Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
MindMed Announces Voluntary Delisting from Cboe Canada
05:00pm, Monday, 01'st Apr 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel p
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
07:00am, Monday, 11'th Mar 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel p
PLTR, MNMD, ODD: Finding Value in the Market
02:46pm, Friday, 08'th Mar 2024
Hilary Kramer discusses finding value in the market. She talks about her stock picks which include Palantir (PLTR), Mind Medicine (MNMD), Oddity (ODD), Prairie Operating (PROP), Starbucks (SBUX), and
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
11:50am, Friday, 08'th Mar 2024
The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.
VANCOUVER, BC , March 8, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral
Psychedelics stocks fly as FDA recognizes Mind Medicine's LSD drug as breakthrough therapy
03:31pm, Thursday, 07'th Mar 2024
Psychedelics stocks traded higher on Thursday as investor optimism returned to the sector on the news that MindMed (NASDAQ:MNMD, NEO:MMED)'s LSD drug candidate was granted breakthrough therapy status
Why Is MindMed (MNMD) Stock Up 32% Today?
09:37am, Thursday, 07'th Mar 2024
MindMed (NASDAQ: MNMD ) stock is on the rise Thursday after the clinical-stage biopharmaceutical company received breakthrough therapy designation from the Food and Drug Administration (FDA). This des
Mind Medicine's LSD drug candidate awarded FDA breakthrough therapy designation; shares soar
09:19am, Thursday, 07'th Mar 2024
MindMed (NASDAQ:MNMD, NEO:MMED) shares soared more than 26% higher before Thursday's opening bell after the biopharmaceutical firm revealed that its drug candidate MM120 has been awarded breakthrough
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
07:13am, Thursday, 07'th Mar 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel p
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
09:00am, Friday, 01'st Mar 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product
Why Is MindMed (MNMD) Stock Up 8% Today?
04:50pm, Monday, 12'th Feb 2024
A positive news update for Mind Medicine (NASDAQ: MNMD ) is elevating the entire psychedelic treatment sector today. Specifically, the U.S. Food and Drug Administration (FDA) has just granted midomafe
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
12:00pm, Tuesday, 09'th Jan 2024
Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year.
What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock
01:31pm, Wednesday, 20'th Dec 2023
Mind Medicine (MindMed) Inc. (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mind Medicine's MM-120 shows promise in Phase 2b trial for Generalized Anxiety Disorder
10:16am, Thursday, 14'th Dec 2023
Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) has announced encouraging results from its Phase 2b clinical trial of MM-120 in treating Generalized Anxiety Disorder (GAD). MM-120, a single-dose lyser
